BUZZ-Astria rises on FDA's orphan drug tag for its genetic disorder treatment
I'm PortAI, I can summarize articles.
Shares of drug developer Astria Therapeuticsrise about 3% to $11.45Co receives FDA orphan drug designation for navenibart for treatment of hereditary angiodemaAngiodema causes swelling of arms, face, legs and intestinal tractOrphan drug tag based on early-to-mid-stage trial, in which drug showed reduced monthly swelling attack rates by 90% to 96% when dosed once or twice over 6 monthsCo expects to get additional results from trial in Q4 and progress navenibart into late-stage trial initiating in Q1 2025Including session’s move, stock up ~47.3% YTD
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments